Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2008-3-27
pubmed:abstractText
We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir. Saquinavir, lopinavir, and darunavir are potent against wild-type HIV-2 isolates and should be preferred as first-line options for HIV-2-infected patients. Other protease inhibitors are less active against HIV-2 than against HIV-1.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/18227188-10747109, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227188-12386343, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227188-14506019, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227188-14565609, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227188-15040537, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227188-15090802, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227188-15635022, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227188-16312183, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227188-16439883, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227188-16464891, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227188-16962136, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227188-17116674, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227188-17147507
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
52
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1545-8
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
pubmed:affiliation
Laboratoire de Virologie, Service de Microbiologie, Hôpital Bichat-Claude Bernard, Paris, France.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't